Indaptus Therapeutics Reports Key Corporate Events
Ticker: INDP · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1857044
| Field | Detail |
|---|---|
| Company | Indaptus Therapeutics, INC. (INDP) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2025 |
| Risk Level | medium |
| Pages | 13 |
| Reading Time | 15 min |
| Key Dollar Amounts | $0.01, $6.00, $6.0 m, $2.03, $1,263,843 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, governance-change, corporate-action
TL;DR
Indaptus Therapeutics filed an 8-K detailing material agreements, equity sales, officer changes, and bylaw amendments.
AI Summary
Indaptus Therapeutics, Inc. filed an 8-K on December 22, 2025, reporting several material events. These include entering into a material definitive agreement, unregistered sales of equity securities, and modifications to security holder rights. The filing also details the departure of directors or officers, election of directors, appointment of officers, and compensatory arrangements. Additionally, amendments to articles of incorporation or bylaws and a change in fiscal year were noted.
Why It Matters
This 8-K filing signals significant corporate actions at Indaptus Therapeutics, potentially impacting its governance, financial structure, and shareholder rights.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate actions including material agreements, equity sales, and changes in governance, which can introduce uncertainty and risk.
Key Players & Entities
- Indaptus Therapeutics, Inc. (company) — Registrant
- December 22, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40652 (identifier) — SEC File Number
- Intec Parent Inc. (company) — Former company name
- 20210414 (date) — Date of former company name change
FAQ
What specific material definitive agreement did Indaptus Therapeutics enter into?
The filing indicates the entry into a material definitive agreement but does not specify the details of the agreement in the provided text.
What were the details of the unregistered sales of equity securities?
The filing notes unregistered sales of equity securities occurred, but the specific terms and amounts are not detailed in the provided excerpt.
Who departed from their roles as directors or officers at Indaptus Therapeutics?
The filing reports the departure of directors or certain officers, but does not name the individuals involved in the provided text.
Were there any amendments to Indaptus Therapeutics' articles of incorporation or bylaws?
Yes, the filing states that there were amendments to the articles of incorporation or bylaws.
Did Indaptus Therapeutics change its fiscal year?
The filing indicates a change in fiscal year was reported.
Filing Stats: 3,828 words · 15 min read · ~13 pages · Grade level 12 · Accepted 2025-12-23 17:22:31
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INDP Nasdaq Capital Mark
- $6.00 — ) of the Company at a purchase price of $6.00 per share of Preferred Stock for aggreg
- $6.0 m — d Stock for aggregate gross proceeds of $6.0 million, subject to the terms and conditi
- $2.03 — ble in shares of Common Stock (based on $2.03 per share) and a cash payment (which in
- $1,263,843 — ler, 216,617 shares of Common Stock and $1,263,843, (ii) in the case of Mr. Sassi, 26,758
- $644,080 — assi, 26,758 shares of Common Stock and $644,080, (iii) in the case of Mr. Linscott, 54,
- $1,307,101 — cott, 54,421 shares of Common Stock and $1,307,101, and (iv) Mr. Newman, 52,204 shares of
- $1,189,275 — wman, 52,204 shares of Common Stock and $1,189,275. The Modification Agreements contain a
- $207,200 — n will receive a cash bonus for 2025 of $207,200 and in connection therewith the parties
Filing Documents
- form8-k.htm (8-K) — 84KB
- ex3-1.htm (EX-3.1) — 81KB
- ex3-2.htm (EX-3.2) — 78KB
- ex10-1.htm (EX-10.1) — 260KB
- ex10-2.htm (EX-10.2) — 39KB
- ex10-3.htm (EX-10.3) — 39KB
- ex10-4.htm (EX-10.4) — 36KB
- ex10-5.htm (EX-10.5) — 38KB
- ex10-6.htm (EX-10.6) — 45KB
- ex10-7.htm (EX-10.7) — 58KB
- 0001493152-25-029107.txt ( ) — 1063KB
- indp-20251222.xsd (EX-101.SCH) — 3KB
- indp-20251222_lab.xml (EX-101.LAB) — 33KB
- indp-20251222_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 23, 2025 INDAPTUS THERAPEUTICS, INC. By: /s/ Nir Sassi Name: Nir Sassi Title: Chief Financial Officer